Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000673967 | SCV000799231 | likely pathogenic | Glycine encephalopathy | 2018-04-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000673967 | SCV002234846 | pathogenic | Glycine encephalopathy | 2021-12-22 | criteria provided, single submitter | clinical testing | Disruption of this splice site has been observed in individual(s) with GLDC-related conditions (PMID: 27362913). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This sequence change affects a donor splice site in intron 19 of the GLDC gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GLDC are known to be pathogenic (PMID: 16601880). This variant is not present in population databases (gnomAD no frequency). ClinVar contains an entry for this variant (Variation ID: 557785). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000673967 | SCV002797761 | likely pathogenic | Glycine encephalopathy | 2022-04-22 | criteria provided, single submitter | clinical testing |